Research programme: anti-RSV therapeutics - Medivir AB

Drug Profile

Research programme: anti-RSV therapeutics - Medivir AB

Alternative Names: Anti-RSV therapeutics research programme - Boehringer Ingelheim; MIV 323; RSV fusion protein inhibitor - Medivir AB

Latest Information Update: 22 Dec 2016

Price : $50

At a glance

  • Originator Boehringer Ingelheim (Canada)
  • Developer Medivir AB
  • Class Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections

Most Recent Events

  • 21 Dec 2016 Research programme: anti-RSV therapeutics - Medivir AB is available for licensing as of 14 Dec 2016. http://www.medivir.se/v5/en/
  • 14 Dec 2016 Preclinical development is ongoing in Sweden
  • 04 Aug 2014 Preclinical trials in Respiratory syncytial virus infections in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top